Immunome, Inc. (NASDAQ:IMNM - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 253,834 shares traded hands during mid-day trading, a decline of 49% from the previous session's volume of 502,314 shares.The stock last traded at $9.75 and had previously closed at $10.60.
Wall Street Analyst Weigh In
A number of analysts recently commented on IMNM shares. Stephens started coverage on Immunome in a research note on Friday, November 8th. They issued an "overweight" rating and a $30.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price target on shares of Immunome in a research note on Monday. Finally, Piper Sandler lowered their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $28.83.
Check Out Our Latest Analysis on IMNM
Immunome Stock Performance
The firm has a 50-day moving average price of $11.72 and a 200-day moving average price of $12.98. The stock has a market cap of $626.67 million, a PE ratio of -1.24 and a beta of 1.90.
Insider Transactions at Immunome
In other Immunome news, insider Robert Lechleider acquired 15,805 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now owns 15,805 shares of the company's stock, valued at $149,831.40. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall acquired 66,057 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. This represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 102,862 shares of company stock valued at $978,045 in the last quarter. 8.60% of the stock is owned by insiders.
Institutional Investors Weigh In On Immunome
Several large investors have recently bought and sold shares of the business. FMR LLC increased its holdings in Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company's stock worth $61,765,000 after buying an additional 13,757 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after purchasing an additional 324,614 shares during the period. Marshall Wace LLP grew its stake in shares of Immunome by 228.5% during the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company's stock valued at $20,731,000 after purchasing an additional 1,191,774 shares during the period. Geode Capital Management LLC grew its stake in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after purchasing an additional 144,557 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after purchasing an additional 237,497 shares during the period. 44.58% of the stock is currently owned by institutional investors.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Further Reading
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
